Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Pharmacoepidemiol Drug Saf. 2022 Oct;31(10):1091-1101. doi: 10.1002/pds.5515. Epub 2022 Aug 10.
To avoid adverse drug reactions, dose reductions are recommended when prescribing selective serotonin reuptake inhibitors (SSRIs) to patients with impaired kidney function. The extent of this practice in routine clinical care is however unknown. We aimed to evaluate the starting and maintenance SSRI doses prescribed to patients stratified by levels of kidney function in real-world practice.
Using data from the Stockholm CREAtinine Measurements (SCREAM) project, we identified 101 409 new users of antidepressants (including 52 286 SSRI users) in the region of Stockholm during 2006-2019, who were ≥50 years of age and had a recent creatinine test taken in order to estimate glomerular filtration rate (eGFR). SSRI dose reduction was defined as a prescribed SSRI dose of ≤0.5 defined daily doses, according to current recommendations. We examined the associations between eGFR and reductions in initial dose and maintenance dose of SSRIs using logistic regression models.
Overall, reductions in initial and maintenance dose were observed among 54.1% and 34.1% of new SSRI users. Nevertheless, about 40% of individuals with an eGFR <30 ml/min/1.73 m were prescribed an SSRI without dose reduction. After adjusting for age and other covariates, lower eGFR was associated with moderately higher odds of dose reduction, for both initial and maintenance dose. Compared to individuals with an eGFR of 90-104 ml/min/1.73 m , the adjusted odds ratios for those with an eGFR <30 ml/min/1.73 m were 1.18 (95% CI: 1.03, 1.36) for initial dose reduction, and 1.49 (1.29, 1.72) for maintenance dose reduction. Stratified analyses showed stronger associations between lower eGFR and SSRI dose reduction among individuals aged 50-64 years and in those receiving prescriptions from psychiatric care.
Lower kidney function was moderately associated with a reduced SSRI dose, independently of age. Prescribing SSRIs to middle-aged and older patients should not only consider patients' age but also their kidney function.
为避免药物不良反应,建议对肾功能受损的患者减少选择性 5-羟色胺再摄取抑制剂(SSRIs)的剂量。然而,这种做法在常规临床实践中的程度尚不清楚。我们旨在评估在真实世界实践中,根据肾功能水平对接受 SSRIs 治疗的患者进行的起始和维持剂量。
使用斯德哥尔摩 CREAtinine 测量(SCREAM)项目的数据,我们确定了 2006-2019 年斯德哥尔摩地区 101409 名新使用抗抑郁药(包括 52286 名 SSRI 使用者)的患者,这些患者年龄≥50 岁,并进行了最近的肌酐检查,以估计肾小球滤过率(eGFR)。根据当前建议,SSRI 剂量减少定义为规定的 SSRI 剂量≤0.5 定义的每日剂量。我们使用逻辑回归模型检查了 eGFR 与初始剂量和维持剂量 SSRIs 减少之间的关联。
总体而言,新 SSRI 使用者中有 54.1%和 34.1%的人减少了初始剂量和维持剂量。然而,仍有约 40%的 eGFR<30ml/min/1.73m 的患者未减少 SSRI 剂量。在调整年龄和其他协变量后,较低的 eGFR 与初始和维持剂量的剂量减少几率中等相关。与 eGFR 为 90-104ml/min/1.73m 的患者相比,eGFR<30ml/min/1.73m 的患者初始剂量减少的调整比值比为 1.18(95%CI:1.03,1.36),维持剂量减少的调整比值比为 1.49(1.29,1.72)。分层分析表明,在年龄在 50-64 岁之间的个体和接受精神科护理处方的个体中,较低的 eGFR 与 SSRI 剂量减少之间的关联更强。
肾功能降低与 SSRI 剂量减少适度相关,独立于年龄。在为中年和老年患者开 SSRIs 处方时,不仅应考虑患者的年龄,还应考虑其肾功能。